New drug aims to stop NMOSD attacks in its tracks
NCT ID NCT05314010
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a drug called MIL62 in 102 people with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord. Participants receive MIL62 or a placebo by IV infusion over several months. The main goal is to see if MIL62 can delay or prevent relapses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MIL62 (a drug given by IV infusion)
What this could lead to
If it works, this could provide a new treatment option to reduce relapses in people with NMOSD.
What could go wrong
This is still an early-to-mid stage trial with only 102 participants. The drug may not prevent relapses better than existing treatments, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ethics Committee of Chinese PLA General Hosptial
Beijing, Beijing Municipality, China